Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice

NCT03521908 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03521908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03521908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
June 13, 2016
Completion date
November 23, 2018
Enrollment
35,756 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism (vte)